J. Brody

发表

Single-Cell Analysis of Human Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating Inflammatory Dendritic Cells.

F. Ginhoux, V. Narang, E. Newell, 2019, Immunity.

Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection

C. Flowers, J. Brody, A. Marabelle, 2019, Clinical Cancer Research.

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

P. Ascierto, K. Harrington, T. de Baère, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.

F. Ginhoux, A. Palucka, M. Merad, 2016, Immunity.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Active and passive immunotherapy for lymphoma: proving principles and improving results.

R. Levy, H. Kohrt, J. Brody, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunosuppressive effects of erythropoietin on human alloreactive T cells.

P. Cravedi, A. Mehrotra, J. Brody, 2014, Journal of the American Society of Nephrology : JASN.

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.

R. Tibshirani, R. Levy, R. Advani, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors

S. Loi, M. Hellmann, L. Emens, 2017 .

Low-affinity CAR T cells exhibit reduced trogocytosis, preventing fratricide and antigen-negative tumor escape while preserving anti-tumor activity

T. Luetkens, D. Atanackovic, A. Welm, 2021, bioRxiv.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016, Journal for ImmunoTherapy of Cancer.

DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance.

James A. Hutchinson, F. Ginhoux, M. Merad, 2015, Immunity.

Cancer vaccines and T cell therapy.

R. Advani, H. Kohrt, D. Czerwinski, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Cpg-loaded Tumor Cell Vaccine Induces Antitumor Cd4 Ϩ T Cells That Are Effective in Adoptive Therapy for Large and Established Tumors Results Cpg Loading Is Required for Effective Vaccination in Tlr9-competent Hosts

H. Kohrt, M. Goldstein, D. Czerwinski, 2022 .

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

Michael R. Green, H. Kohrt, R. Luong, 2013, The Journal of clinical investigation.

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

A. Jimeno, J. Welsh, J. Grilley-Olson, 2020, Journal for ImmunoTherapy of Cancer.

Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination

M. Merad, T. Marron, Adeeb H. Rahman, 2019, Nature Medicine.

Dendritic cells and lymphoma cells: come together right now.

N. Bhardwaj, J. Brody, 2015, Blood.

Natural toll-like receptor agonists in prophylactic vaccines for dendritic cell activation

J. Brody, L. Hammerich, P. Peng, 2015, Journal of Immunotherapy for Cancer.

In situ vaccination as a therapy for low-grade lymphoma.

J. Brody, 2015, Clinical advances in hematology & oncology : H&O.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

A. López-Guillermo, F. Bosch, A. Nagler, 2019, The Lancet. Haematology.

Signaling pathways in lymphoma: pathogenesis and therapeutic targets.

J. Myklebust, J. Gabrilove, D. McFarland, 2013, Future oncology.

Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas.

K. Harrington, A. Tse, J. Strauss, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

DC-SIGN + Macrophages C ontrol the Induction of Transplantation Tolerance Graphical

James A. Hutchinson, F. Ginhoux, M. Merad, 2015 .

CD28 receptor endocytosis is targeted by mutations that disrupt phosphatidylinositol 3-kinase binding and costimulation.

H. Schneider, C. Rudd, H. Kang, 1998, Journal of immunology.

A critical role for fas-mediated off-target tumor killing in T cell immunotherapy.

M. Merad, S. Parekh, Alessia Baccarini, 2020, Cancer discovery.

Cancer vaccines: the next immunotherapy frontier

I. Melero, B. Brown, J. Brody, 2022, Nature Cancer.

A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells.

R. Hoffman, J. Mascarenhas, W. Kowalczyk, 2016, Blood.

Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

Tamara J Laskowski, J. Taube, P. Ascierto, 2022, Journal of Translational Medicine.

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies.

I. Flinn, A. Feldman, J. Nemunaitis, 2020, Blood advances.

Retrospective analysis of prognosticators in patients with relapsed Hodgkin’s Lymphoma treated with autologous transplant: results of a single center

E. Moshier, L. Isola, J. Brody, 2013, Medical Oncology.

Dual Inhibition of CDK4/Rb and PI3K/AKT/mTOR Pathways by ON123300 Induces Synthetic Lethality in Mantle Cell Lymphomas

E. Reddy, S. Baker, S. Parekh, 2015, Leukemia.

Idiotype vaccine strategies for treatment of follicular lymphoma.

C. Flowers, J. Brody, R. Sinha, 2011, Future oncology.

Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909

R. Advani, D. Czerwinski, S. Horning, 2008 .

A case of complete heart block reverting to normal sinus rhythm after treatment for cardiac invasive Burkitt’s lymphoma

J. Knowles, J. Brody, Amy B Elliott, 2007, Annals of Hematology.

In CAR T cell-treated lymphomas, the T cell rich get richer

T. Anagnostou, J. Brody, 2022, Nature Medicine.

NF-κB Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome

Ash A. Alizadeh, H. Kohrt, R. Houot, 2010 .

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.

J. Nemunaitis, R. Doebele, M. Hellmann, 2017 .

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.

A. Goldberg, R. Kreisberg, D. Capuzzi, 1998, The American journal of cardiology.

Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity

M. Merad, D. Oreper, A. García-Sastre, 2022, Nature Communications.

Using Signaling Pathways to Overcome Immune Tolerance to Tumors

E. Engleman, J. Brody, L. Soares, 2004, Science's STKE.

Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19

G. Criner, R. Miller, A. Hotson, 2020, medRxiv.

A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity

Ronald Levy, Shoshana Levy, S. Levy, 2012, Proceedings of the National Academy of Sciences.

Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.

S. Jagannath, D. Madduri, S. Parekh, 2020, Clinical lymphoma, myeloma & leukemia.

Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.

F. Hodi, S. Hu-Lieskovan, J. Brody, 2021, European journal of cancer.

Combination strategies to enhance antitumor ADCC.

H. Kohrt, R. Houot, M. Goldstein, 2012, Immunotherapy.

Anti-tumor T-cell homeostatic activation is uncoupled from homeostatic inhibition by checkpoint blockade.

M. Merad, T. Marron, B. Brown, 2019, Cancer discovery.

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy

A. Laganà, S. Jagannath, J. Teruya-Feldstein, 2021, Nature Medicine.

Treatment of mantle cell lymphoma: current approach and future directions.

R. Advani, J. Brody, 2006, Critical reviews in oncology/hematology.

Local Immunotherapies of Cancer

T. Marron, J. Brody, L. Hammerich, 2018 .

SOX11 augments BCR signaling to drive MCL-like tumor development.

R. Shaknovich, Adeeb H. Rahman, S. Parekh, 2018, Blood.

Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.

O. Elemento, E. Cesarman, W. Tam, 2015, Blood.

Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma

J. Dudley, A. Laganà, S. Jagannath, 2019, Clinical Cancer Research.

In-situ tumor vaccination: Bringing the fight to the tumor

H. Kohrt, R. Pierce, S. Pai, 2015, Human vaccines & immunotherapeutics.

Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.

S. Jagannath, E. Reddy, S. Parekh, 2016, Cancer research.

Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant.

J. Brody, R. Levy, 2009, Immunotherapy.

An Update on the Use of Immunotherapy in the Treatment of Lymphoma

T. Marron, J. Brody, M. Kalac, 2017, Current Hematologic Malignancy Reports.

Lymphoma: Immune Evasion Strategies

M. Merad, B. Brown, J. Brody, 2015, Cancers.

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

Ash A. Alizadeh, H. Kohrt, R. Houot, 2011, Blood.

β-Catenin-Independent Activation of TCF1/LEF1 in Human Hematopoietic Tumor Cells through Interaction with ATF2 Transcription Factors

Joshua Brody, Stuart A. Aaronson, Marek Mlodzik, 2013, PLoS genetics.

Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

Tamara J Laskowski, J. Taube, P. Ascierto, 2022, Journal of translational medicine.

Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.

C. Flowers, T. Marron, J. Brody, 2016, Immunotherapy.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

J. Friedberg, M. Shipp, P. L. Bergsagel, 2016, Journal of Immunotherapy for Cancer.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

H. Kohrt, J. Wolchok, L. Zitvogel, 2016, Journal of Immunotherapy for Cancer.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

J. Friedberg, S. Ansell, D. Porter, 2020, Journal for ImmunoTherapy of Cancer.

Intratumoral checkpoint subversion as a strategy for minimizing adverse effects

Nina Bhardwaj, Sacha Gnjatic, Leah Alabanza, 2014, Oncoimmunology.

Pattern recognition receptors: immune targets to enhance cancer immunotherapy.

C. Caux, S. Depil, J. Brody, 2019, Annals of Oncology.

Pattern recognition receptors: immune targets to enhance cancer immunotherapy

C. Caux, S. Depil, J. Brody, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

T. Choueiri, R. Heist, M. Sznol, 2019, Cancer discovery.

Signaling pathways in lymphoma: pathogenesis and therapeutic

J. Myklebust, J. Gabrilove, D. McFarland, 2013 .

Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion

T. Luetkens, D. Atanackovic, A. Welm, 2022, Leukemia.

Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.

Michael R. Green, A. Alizadeh, H. Kohrt, 2017, Blood.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

A Case of a Laryngeal MALT Lymphoma in a Patient with a History of Gastric MALT

E. Demicco, M. Teng, K. Dharmarajan, 2015, Case reports in hematology.

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

A. Younes, B. Hodkinson, J. Brody, 2020, Translational oncology.

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.

Ash A. Alizadeh, Michael R. Green, H. Kohrt, 2013, Blood.

In situ vaccination for the treatment of cancer.

H. Kohrt, N. Bhardwaj, J. Brody, 2016, Immunotherapy.

Deep B and T Cell Repertoire Sequencing to Evaluate Minimal Residual Disease and T Cell Responses in a Therapeutic Vaccine Trial for Mantle Cell Lymphoma

R. Advani, H. Kohrt, D. Czerwinski, 2012 .

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

T. Choueiri, R. Heist, M. Sznol, 2019 .

Immunomodulation Within a Single Tumor Site to Induce Systemic Antitumor Immunity: In Situ Vaccination for Cancer

J. Brody, L. Hammerich, 2016 .

In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf

J. Brody, A. Binder, L. Hammerich, 2015, Molecular oncology.

Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors.

M. Goldstein, D. Czerwinski, J. Brody, 2009, Blood.

T-regulatory cells and cures large lymphoma tumors Immunotransplantation preferentially expands T-effector cells over

M. Goldstein, D. Czerwinski, J. Brody, 2008 .

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial

Ash A. Alizadeh, R. Advani, D. Czerwinski, 2020, The Journal of experimental medicine.

Primary Neurolymphomatosis Presenting With Polyradiculoneuropathy Affecting One Lower Limb

F. Lublin, S. Morgello, J. Brody, 2015, Journal of clinical neuromuscular disease.

Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

P. Zinzani, N. Bartlett, J. Kuruvilla, 2022, Leukemia & lymphoma.

Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL)

Qingshan Li, G. Bhagat, Rosalind L. Ang, 2020, Cell Death & Disease.

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.

R. Tibshirani, R. Advani, D. Czerwinski, 2012, Blood.

cells infiltrating follicular lymphoma tumors from peripheral T cells High PD-1 expression and suppressed cytokine signaling distinguish T

Michael R. Green, R. Houot, D. Czerwinski, 2013 .

1141PDCA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study

J. Lee, M. Ahn, Y. Bang, 2017 .

Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.

J. Infante, A. Daud, Hongwei Wang, 2017 .

Erratum: Depleting tumor-specific Tregs at a single site eradicates disseminated tumors (Journal of Clinical Investigation (2013) 123:11 (4980) DOI:10.1172/JCI73340)

Michael R. Green, H. Kohrt, R. Luong, 2013 .

ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.

J. Brody, Jun Zhu, Yongping Song, 2020, Future oncology.

Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination

M. Merad, T. Marron, Adeeb H. Rahman, 2019, Nature Medicine.

Abstract CT091: Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors

J. Zha, J. Grilley-Olson, D. Hong, 2017 .

Not just neighbours: positive feedback between tumour-associated macrophages and exhausted T cells

J. Brody, Gabrielle S Lubitz, 2021, Nature reviews. Immunology.

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

P. Abrisqueta, F. Awan, K. Drott, 2022, Blood.

In situ vaccine for low-grade lymphoma: Combination of intratumoral Flt3L and poly-ICLC with low-Dose radiotherapy.

S. Kim-Schulze, T. Marron, N. Bhardwaj, 2015 .

Splenic diffuse large B-cell lymphoma in a patient with type 1 Gaucher disease: diagnostic and therapeutic challenges

R. Advani, D. Bingham, J. Brody, 2006, Annals of Hematology.

Liposomal Vincristine as a Bridge Therapy Prior to CAR-T Therapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma?

J. Brody, A. Steinberg, Shafinaz Hussein, 2019, International journal of hematology-oncology and stem cell research.

Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results.

Ash A. Alizadeh, R. Advani, H. Kohrt, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

A. López-Guillermo, A. Nagler, B. K. Masouleh, 2017 .

In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study

R. Tibshirani, Y. Natkunam, R. Advani, 2010 .

Use of etanercept in management of tyrosine kinase-inhibitor-induced erythema nodosum

J. Brody, J. Levitt, A. Keyzner, 2020, JAAD case reports.

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

E. Piccione, N. Bartlett, C. Carlo-Stella, 2022, Blood.

Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.

T. Phillips, P. Lugtenburg, J. Brody, 2022, Journal of Clinical Oncology.

First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.

J. Brody, F. Offner, S. Snauwaert, 2022, Journal of Clinical Oncology.

Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming

M. Merad, S. Rose, D. Oreper, 2023, Journal for ImmunoTherapy of Cancer.

90 Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway

M. Merad, J. Rossi, S. Parekh, 2020, Journal for ImmunoTherapy of Cancer.

Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)

P. Ascierto, T. Kirchhoff, B. Fox, 2023, Journal of Translational Medicine.

Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)

L. Sehn, J. Brody, I. Avivi, 2022, Blood.

HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATE

S. de Vos, J. Brody, S. Snauwaert, 2023, Hematological Oncology.

Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.

S. de Vos, J. Brody, F. Offner, 2023, Journal of Clinical Oncology.

Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.

A. Salar, N. Bartlett, C. Carlo-Stella, 2023, Journal of Clinical Oncology.

Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL)

Qingshan Li, G. Bhagat, Rosalind L. Ang, 2020, Cell Death & Disease.

Combining In Situ Vaccination with Immune Checkpoint Blockade Induces Long-Term Regression of Lymphoma Tumors

A. Salazar, J. Brody, T. Keler, 2016 .

Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma

R. Tibshirani, R. Advani, H. Kohrt, 2014 .

in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses

R. Advani, H. Kohrt, D. Czerwinski, 2012 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

Ash A. Alizadeh, H. Kohrt, R. Houot, 2011, Blood.

Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.

F. Ginhoux, A. Palucka, M. Merad, 2016, Immunity.

A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors.

H. Kohrt, M. Goldstein, D. Czerwinski, 2011, Blood.

Liposomal Vincristine as a Bridge Therapy Prior to CAR-T Therapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma?

J. Brody, A. Steinberg, Shafinaz Hussein, 2019, International journal of hematology-oncology and stem cell research.

In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf

J. Brody, A. Binder, L. Hammerich, 2015, Molecular oncology.

Holbrook Kohrt: In Memoriam (1977–2016)

J. Brody, Antonia M. S. Müller, Roch Houot, 2016, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Cancer vaccines and T cell therapy.

R. Advani, H. Kohrt, D. Czerwinski, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

DC-based cancer vaccines: lessons from clinical trials.

E. Engleman, J. Brody, J. Brody, 2004, Cytotherapy.

Local Treg Immunomodulation Cures Metastatic Lymphoma Including CNS Sites

H. Kohrt, R. Luong, V. Tse, 2011 .

Abstract A02: Beta-catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors

Sathish Kumar Mungamuri, S. Aaronson, G. Akiri, 2013 .

Turning a Tumor into a Vaccine Factory: In Situ Vaccination for Low-Grade Lymphoma

T. Marron, N. Bhardwaj, J. Brody, 2014 .

Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585]

M. Merad, S. Kim-Schulze, N. Bhardwaj, 2014, Journal of Immunotherapy for Cancer.